The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...
A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...
HealthDay on MSN13d
FDA Approves Gemtesa for Overactive Bladder in Men With BPHGemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
A Dundalk-area man is the first person in Canada to receive a new, publicly funded treatment that better targets prostate cancer cells and is shown to prolong life.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback